GeoVax Labs Inc. (NASDAQ:GOVX) Sees Large Drop in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 281,773 shares, a decrease of 43.5% from the September 15th total of 498,698 shares. Approximately 3.8% of the company’s shares are sold short. Based on an average daily trading volume, of 241,876 shares, the short-interest ratio is currently 1.2 days.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GOVX shares. Noble Financial reiterated an “outperform” rating on shares of GeoVax Labs in a report on Tuesday, September 15th. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $150.00.

GeoVax Labs Stock Down 7.6%

Shares of GeoVax Labs stock traded down $0.02 during trading hours on Friday, hitting $0.24. The company’s stock had a trading volume of 145,494 shares, compared to its average volume of 1,904,835. GeoVax Labs has a 1-year low of $0.23 and a 1-year high of $15.25. The business has a fifty day moving average of $0.48 and a 200 day moving average of $1.06. The company has a market capitalization of $1.76 million, a PE ratio of -0.02 and a beta of 3.69.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Monday, July 27th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19. On average, sell-side analysts anticipate that GeoVax Labs will post -4.94 earnings per share for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc is a biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based primarily on a vaccine platform that combines a modified vaccinia Ankara (MVA) viral vector with virus-like particles (VLPs) to stimulate both antibody and cellular immune responses.

GeoVax’s development programs have included GEO-CM04S1, a next-generation COVID-19 vaccine candidate; GOVX-B11, an investigational HIV vaccine designed to generate broadly protective immune responses; and GOVX-CHIKV, a vaccine candidate targeting chikungunya virus.